Articles

81. Patient Demand, Vaccines, And Drug Delivery: Q&A With Steve Wick Of 3M Drug Delivery Systems 4/24/2014

    New technologies are changing the drug delivery approaches used for both small and large molecule manufacturers. Additionally, the more empowered patient is causing many pharma companies to re-evaluate their drug delivery strategies. We spoke with Steve Wick, Senior Technical Director for 3M Drug Delivery Systems, about these topics as well as how the drug delivery landscape might change over the next 5 to 10 years.  

    What technologies are currently changing drug delivery approaches for small molecules? For large molecules? How will these advances impact the pharmaceutical industry?

    For small molecules specifically, I believe that we will see two different trends in drug delivery. The first will be toward the targeting of drug delivery through the use of technology such as nanoparticles or even aptamers. 

82. Vaccine And Virus Manufacturing And Testing 4/14/2014

    Charles River Biologics Testing Solutions can help you expedite your vaccine development program by providing you with manufacturing for early-phase clinical trials through to lot release for commercial products.

83. New Technologies In Fill-Finish May Bring Brand Loyalty Along With Improved Patient Safety 4/1/2014

    In January 2014, Senator Charles Schumer (D-NY) called on drug makers, the FDA, and the Consumer Product Safety Commission to help reduce the number of emergency room visits among children who are accidentally given the wrong dosage. He argues that implementing flow-restricting devices on liquid formulations could prevent approximately 10,000 emergency room visits each year and would cost only a matter of cents per bottle.

84. Development and Manufacturing Equipment List 1/13/2014

    Norwich is a leader in solid dose pharmaceutical production. We offer expertise, comprehensive manufacturing and packaging support from clinical trial through scale-up and to commercial launch.

85. OSO Biopharmaceuticals Capabilities Overview 1/3/2014

    OSOBio is a contract manufacturing organization (CMO) that focuses on biologic and pharmaceutical injectable finished drug products- (sterile liquid, liquid suspension and lyophilized formulations)

86. OSO Biopharmaceuticals Brochure 1/3/2014

    OsoBio delivers the sterile contract manufacturing and drug development services you require - regardless of the scale or complexity of your sterile injectable.

87. Anticipating Success: Meeting The Inherent Challenges Of Complex Drug Substances 9/17/2013

    Realizing the full potential of a novel injectable drug compound is no small task. In the months and years that lead from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can slow development to a halt, often at key stages.

88. The Environmental Impact of Clinical Trials 8/8/2013

    For many years it has been almost universally accepted that there are various sources that may impact or cause disease among which biological, social, and environmental differences have all been investigated. Many clinical trials have been conducted to assess the impact of the environment on outcomes e.g., the effect of the environment on the outcome of studies assessing the efficacy of drugs for patients with dry-eye syndrome, the impact of diet on obesity and cardiovascular disease, and the impact of the environment on autoimmune diseases have all been studied, as have many other interactions.

89. Adding Value To The Drug Development Process 4/30/2012

    Life science companies can gain advantages from working with external partners that can bridge the divide between drug development and commercialization. By William Crown, Ph.D.

90. Kemwell Overview 3/29/2012
    Manufacturing customers include top pharmaceutical companies – Allergan, Bayer, GSK, J&J, Pfizer, Teva, and Novartis, as well as small emerging biotech.